Speculation, Rumors and

No disrespect to any company presenting today but for all practical purposes JPM ended last night. Yes, we know there a few remaining presentations today, but the reality is the cab lines are back to normal, Uber is no longer up charging rides and you can get a hotel room in San Francisco without sacrificing the kid’s college fund.

Not to get too far off the track but with hotel rates being what they are and the homeless issue which is very prevalent in the downtown area being what is, many attendees have been questioning the value of returning . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

What it is, what it isn’t and likely won’t be

It's now official as Tandem has the coolest toy in the toy chest with the company announcing the Control IQ is now commercially available. The Control IQ has replaced the 670G from Medtronic as the best hybrid closed loop insulin delivery system. How long this lasts is anyone’s guess as Insulet announced at JPM the Horizon should be here in the second half of this year, making it the third entry into the hybrid closed loop category.

Based on what we know and what is available in the public domain we’d say it will be a tough . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

JPM Day Two Final

We’ll probably catch some flak for saying this but we almost feel sorry for Lilly. Not only are they being accused of putting profits before patients lives no matter how many programs they offer for lower price insulin. Before their presentation yesterday afternoon a small group of protestors gathered outside the event this time protesting Lilly’s treatment of animals. Perhaps we should look at these protests differently and not as the annoyances they seem to be. Perhaps it’s a sign of how deeply healthcare has become engrained in our society. Monday it was global warming, Tuesday it . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

JPM Day Two Monring Wrap Up

Before we go onto the news of the day allow us to finish up on Abbott. Other than learning that Libre2 is aways away we also asked why the company continued to invest in Bigfoot. Here as well the answer was somewhat confusing as the company noted they like the Bigfoot platform but in the same answer pointed out there other partnerships with the insulin companies. Now to us this seems almost counter intuitive as if the Bigfoot platform is so good why also partner with the insulin companies who are developing Tyler’s of their own and who as . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

Libre2 Update – BIG NEWS

Ok let’s get right to the point as we only have short time between presentations and this is BIG news – as promised we asked Abbott about the status of the Libre2, specifically when would it get here and will it get an iCGM designation. Remember last week at CES Abbott representatives were telling attendees that Libre2 would not be here for another year, which if accurate would be a major blow to Abbott.

Well according to Abbott CEO Robert Ford they have submitted more data and information to the FDA and are confident they will gain iCGM.

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

JPM Day One Afternoon Sessions

Since we’ve started a trend lets run with some of the non-business stuff before we get to the real point of this conference. While we haven’t quite figured out what the climate crisis has to do with healthcare a group of climate activists got into the conference for a very loud and thankfully very short protest. Guess the high cost of prescription medications are somehow contributing to global warming, who knew?

Next in the ultimate sign of hubris, actually we think its obnoxious, inside the Hilton is a vending machine that dispenses champagne. Yep according to a . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

JPM Day One Morning Session

Before we get into what’s gone on this morning let’s first reveal the answer to a question we know everyone wants answered – the bags this year are a swanky grey with orange trim. Now onto some more mundane yet equally important items.

Although Medtronic was not the first presentation we witnessed this morning it was somewhat revealing. It wasn’t that long ago that here at JPM when it came to their diabetes franchise the company was boosting about projected high double digit growth rates and a stand alone CGM platform that would generate billions in revenue. Fast . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

The lull before the storm

Since it’s Sunday and most of us will be watching football most people will likely read this after JPM is underway. As we head to that beautiful city by the bay which just so happens has one hell of a football team our thoughts turn an issue that many won’t want to talk about but needs to be discussed.

Although we didn’t report on it during CES several funding deals were announced the most recent being Companion securing more capital. Before that Vitra Health announced more money coming in and of course Livongo did another deal this . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

CES Second Impressions

Well we don’t have any BIG news today although being here with all these “smart” devices does make us long for the days when it was ok to be dumb. Everything from vacuum cleaners, toothbrushes and yes even vibrators are “smart” now. It does make one wonder how us older folk were able to survive, raise families and manage our diabetes without every toy in the toy chest being so damn smart.

Speaking of which the Digital Health summit here is generating lots of buzz, shocking we know, as every employer is seeking that magic bullet which will lower . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.

CES First Impressions

Before we get started with our first impression of CES here in Sin City let’s get the most stunning news out first. While visiting the Abbott booth an Abbott representative stated that Libre2 will not be here in the US for another year. This comment came in response to a question asked by an attendee, we just happened to standing next to the guy. Talk about luck but this is Vegas, and should this statement be accurate JPM just got more interesting.

As we have noted before we have no clue as to why the FDA has . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.